COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study
Endocrine-Related Cancer · 2023
DOI: 10.1530/erc-22-0395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Nicola Fazio und 36 weiteren Autor:innen. Beteiligte Einrichtung: Division of gastrointestinal medical oncology and neuroendocrine tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: COVID-19, Pancreatic Neoplasms, Neuroendocrine Tumors, Diabetes Mellitus. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of gastrointestinal medical oncology and neuroendocrine tumors, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
- Molecular Medicine Program, University of Pavia, Pavia, Italy.
- Division of Medical Oncology Mayo Clinic, Rochester, Minnesota, USA.
- Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
- Division of Medical Oncology, National Cancer Institute, Milan, Italy.
- Neuroendocrine Tumor Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism, Hadassah Medical Center and Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
ORCID-Profile: Nicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, Simona Grozinsky-Glasberg, Clotilde Sparano, Sara Massironi, Johannes Hofland
Zitieren
APA
Fazio, N., Gervaso, L., Halfdanarson, T. R., Sonbol, M., Eiring, R. A., Pusceddu, S., Prinzi, N., Lombardi Stocchetti, B., Grozinsky-Glasberg, S., Gross, D. J., Walter, T., Robelin, P., Lombard-Bohas, C., Frassoni, S., Bagnardi, V., Antonuzzo, L., Sparano, C., Massironi, S., Gelsomino, F., …, & Spada, F. (2023). COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-22-0395
Vancouver
Fazio N, Gervaso L, Halfdanarson TR, Sonbol M, Eiring RA, Pusceddu S, et al. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study. Endocrine-Related Cancer. 2023. doi:10.1530/erc-22-0395
BibTeX
@article{Fazio2023,
author = {Fazio, Nicola and Gervaso, Lorenzo and Halfdanarson, Thorvardur R and Sonbol, Mohamad and Eiring, Rachel A and Pusceddu, Sara and Prinzi, Natalie and Lombardi Stocchetti, Benedetta and Grozinsky-Glasberg, Simona and Gross, David J and Walter, Thomas and Robelin, Patrick and Lombard-Bohas, Catherine and Frassoni, Samuele and Bagnardi, Vincenzo and Antonuzzo, Lorenzo and Sparano, Clotilde and Massironi, Sara and Gelsomino, Fabio and Bongiovanni, Alberto and Ranallo, Nicoletta and Tafuto, Salvatore and Rossi, Maura and Cives, Mauro and Rasul Kakil, Ibrahim and Hamid, Hytam and Chirco, Alessandra and Squadroni, Michela and La Salvia, Anna and Hernando, Jorge and Hofland, Johannes and Koumarianou, Anna and Boselli, Sabrina and Tamayo, Darina and Mazzon, Cristina and Rubino, Manila and Spada, Francesca},
title = {COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study},
journal = {Endocrine-Related Cancer},
year = {2023},
doi = {10.1530/erc-22-0395}
}
EUVIMED